OPRX, US68401U2042

OptimizeRx expands OpenPath reach. B. Riley sets USD 11.00 target for OptimizeRx stock

Published on 10/16/2026 at 00:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue fell to USD 20.50 million and B. Riley set a USD 11.00 target. OptimizeRx stock has Q3 results scheduled for November 5, 2026.

Operating milestones and valuation

OptimizeRx announced its OpenPath integration on September 22, 2026, with availability planned for the fourth quarter of 2026.
Second-quarter 2026 revenue was USD 20.50 million, while net income was a USD 0.70 million loss.
B. Riley set an USD 11.00 price target for OptimizeRx on September 29, 2026.
OptimizeRx is scheduled to report third-quarter 2026 results on November 5, 2026.

OPRX, US68401U2042, Illustration mit AI erstellt.

OptimizeRx Corporation announced an OpenPath integration on September 22, 2026, and B. Riley set an USD 11.00 price target for the company on September 29. The integration is intended to make OptimizeRx's authenticated point-of-care inventory available to advertisers using The Trade Desk in the fourth quarter of 2026, according to MarketScreener. MarketBeat reported that the target rose to USD 11.00 from USD 10.00.

OpenPath adds a distribution channel

The September 22 announcement connects OptimizeRx's electronic health record point-of-care inventory with The Trade Desk's OpenPath supply-path platform. OptimizeRx said the inventory was expected to become available during the fourth quarter of 2026, giving the arrangement a defined implementation window. The company describes its platform as a healthcare technology system linking life sciences brands with healthcare professionals and patients.

What changed in the second quarter?

OptimizeRx reported USD 20.504 million of revenue for the second quarter of 2026, down from USD 29.195 million in the second quarter of 2025. Net income shifted from a USD 1.532 million profit to a USD 0.703 million loss over the same comparison, according to MarketBeat. The standardized financial statements also show USD 8.611 million of operating cash flow for the quarter.

When are the next results due?

MarketBeat lists November 5, 2026, as the estimated date for OptimizeRx's third-quarter results, with the announcement expected after the market closes and the conference call scheduled for 4:30 p.m. ET. The same report gives a consensus revenue estimate of USD 21.19 million and consensus earnings per share of USD 0.18.

Nasdaq valuation remains below target

The last available primary-market quote was USD 8.85 on October 15, 2026, at 4:00 p.m. ET on Nasdaq. The USD 166.7 million market capitalization and the USD 4.54 to USD 22.25 52-week range frame the valuation backdrop, while the USD 11.00 B. Riley target sits above the latest quoted level.